Rivulet Media Inc (fka RIVU)

[Hegotgame]

Regen BioPharma Files Investigational New Drug (IND) Application With FDA
on HemaXellerate I(TM) Stem Cell Drug for Aplastic Anemia
Clinical Trial to
Evaluate "First in Class" Approach to Bone Marrow Failure Diseases


SAN DIEGO, CA, Feb 05, 2013 (MARKETWIRE via COMTEX) -- Regen BioPharma a
wholly-owned subsidiary of Bio-Matrix Scientific Group Inc. (PINKSHEETS: BMSN),
announced today filing of an Investigational New Drug (IND) application with the
FDA to initiate clinical trials assessing the company's HemaXellerate I(TM) stem
cell drug in patients with drug-refractory aplastic anemia.

HemaXellerate I(TM) is a patient-specific composition of cells that have
previously been demonstrated to repair damaged bone marrow and stimulate
production of blood cells based on previous animal studies. The company,
together with an internationally-renowned group of stem cell researchers,
recently published the scientific basis for the HemaXellerate I(TM) product
which may be found at
http://www.translational-medicine.com/content/pdf/1479-5876-10-231.pdf.

"Currently patients with aplastic anemia who are resistant to drugs and
ineligible for bone marrow transplant have no therapeutic options. We are
fortunate to be in the position to have developed a novel approach to
potentially treat this terrible condition," said David Koos, CEO of Bio-Matrix.
"To our knowledge the HemaXellerate I(TM) product is the only therapy that has
potential to simultaneously block the underlying cause of aplastic anemia while
at the same time rebuilding the bone marrow tissue that has been damaged by the
disease."

If the clinical trial is successful, the company plans to expand use of
HemaXellerate I(TM) to other conditions associated with bone marrow dysfunction,
with the overall goal of entering the hematopoietic growth factor market. This
market is substantial in size and currently includes drugs such as Neupogen(R),
Neulasta(R), Leukine(R) and Revolade(R).

"Current drug-based approaches for healing bone marrow damage involve "flooding"
the body with growth factors, which is extremely expensive and causes unintended
consequences because of lack of selectivity," said Dr. Vladimir Bogin, CEO of
Chromos Pharma (a contract research organization), which collaborated with Regen
on filing the IND and member of the Company's Scientific Advisory Board. "Based
on our data HemaXellerate I(TM) possesses the advantage delivering an optimized
cellular mixture that produces the needed growth factors at the specific
location in the bone marrow niche."

The planned clinical trial anticipates recruiting 10 patients who have failed
standard of care, which will be treated with HemaXellerate I(TM) and followed
for safety parameters and signals of efficacy. Therapeutic effects will be
quantified based on immunological measurements, as well as improvement in blood
counts. Patients in the trial will be assessed for one year, however, because
the trial is unblinded, data will be available as the study progresses.

About Bio-Matrix Scientific Group Inc. and Regen BioPharma, Inc.:

Bio-Matrix Scientific Group, Inc. (PINKSHEETS: BMSN) is a biotechnology company
developing regenerative medicine therapies. The Company is focused on human
therapies that address unmet medical needs. Specifically, Bio-Matrix Scientific
Group Inc. is looking to increase the quality of life through therapies
involving stem cell treatments. These treatments are focused in areas relating
to cardiovascular, hematology, oncology and other indications.

Regen BioPharma, Inc., a subsidiary of Bio-Matrix Scientific Group, Inc.
(PINKSHEETS: BMSN), is a biotechnology company focused on identifying
undervalued regenerative medicine patents in the stem cell space and rapidly
advancing these technologies through pre-clinical and Phase I/ II clinical
trials. To follow our development, visit us at www.regenbiopharma.com.

Disclaimer

This news release may contain forward-looking statements. Forward-looking
statements are inherently subject to risks and uncertainties, some of which
cannot be predicted or quantified. Future events and actual results could differ
materially from those set forth in, contemplated by, or underlying the
forward-looking statements. The risks and uncertainties to which forward looking
statements are subject include, but are not limited to, the effect of government
regulation, competition and other material risks





Contact:



Bio-Matrix Scientific Group, Inc.

David R. Koos, PhD

Chairman & Chief Executive Officer

619-702-1404

www.bmsn.us

Email Contact





SOURCE: Bio-Matrix Scientific Group, Inc.




CONTACT: http://www.bmsn.us/